Aprea Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Aprea Therapeutics, Inc. (APRE) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $103.19 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- Aprea Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $103.19K, a 24.53% decline year-over-year.
- Aprea Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $101.07K, a 14.81% decline year-over-year.
- Aprea Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $113.75K, a 23.70% decline year-over-year.
- Aprea Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $136.73K, a 6.41% increase year-over-year.
- Aprea Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $478.14K, a 2.31% decline from fiscal 2024.
- Aprea Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $489.44K, a 10.12% increase from fiscal 2023.
- Aprea Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $444.46K, a 97.38% decline from fiscal 2022.
- Aprea Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $16.98M, a 117.33% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $103.19K 10-Q · filed 2026-08-12 | $204.26K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $101.07K 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $478.14K 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $113.75K 10-Q · filed 2025-11-12 | $250.48K derived: sum of 2 quarters · filed 2026-08-12 | $369.12K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $136.73K 10-Q · filed 2026-08-12 | $255.36K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $118.63K 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $489.44K 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $149.09K 10-Q · filed 2025-11-12 | $277.58K derived: sum of 2 quarters · filed 2025-11-12 | $363.41K derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $128.49K 10-Q · filed 2025-11-12 | $214.32K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $85.83K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $444.46K 10-K · filed 2025-03-25 | |||
| 2023-09-30 | $76.03K 10-Q · filed 2024-11-07 | $345.35K derived: sum of 2 quarters · filed 2024-11-07 | $361.60K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $269.32K 10-Q · filed 2024-11-07 | $285.57K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $16.24K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $16.98M 10-K · filed 2024-03-26 | |||
| 2022-09-30 | $38.24K 10-Q · filed 2023-11-09 | $14.84M derived: sum of 2 quarters · filed 2023-11-09 | $16.92M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $14.80M 10-Q · filed 2023-11-09 | $16.89M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $2.08M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $7.81M 10-K · filed 2024-03-26 | |||
| 2021-09-30 | $2.04M 10-Q · filed 2022-11-09 | $3.90M derived: sum of 2 quarters · filed 2022-11-09 | $5.72M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $1.86M 10-Q · filed 2022-11-09 | $3.69M 10-Q · filed 2021-11-08 | ||
| 2021-03-31 | $1.82M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $4.98M 10-K · filed 2023-03-30 | |||
| 2020-09-30 | $1.39M 10-Q · filed 2021-11-08 | $2.65M derived: sum of 2 quarters · filed 2021-11-08 | $3.55M derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $1.26M 10-Q · filed 2021-08-12 | $2.16M 10-Q · filed 2021-11-08 | ||
| 2020-03-31 | $905.47K 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $1.35M 10-K · filed 2022-03-15 | |||
| 2019-09-30 | $246.22K 10-Q · filed 2020-11-06 | $433.19K derived: sum of 2 quarters · filed 2020-11-06 | $531.13K derived: sum of 3 quarters · filed 2020-11-06 | |
| 2019-06-30 | $186.96K 10-Q · filed 2020-08-11 | $284.91K 10-Q · filed 2020-11-06 | ||
| 2019-03-31 | $97.95K 10-Q · filed 2020-08-11 | |||
| 2018-12-31 | $329.18K 10-K · filed 2021-03-16 | |||
| 2018-09-30 | $79.79K 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | $169.85K 10-Q · filed 2019-11-14 | |||
| 2017-12-31 | $395.44K 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |